VEA
Virtus ETF Advisers Portfolio holdings
AUM
$75.7M
1-Year Return
23.01%
This Quarter Return
-0.88%
1 Year Return
+23.01%
3 Year Return
+79.79%
5 Year Return
+153.94%
10 Year Return
–
AUM
$227M
AUM Growth
-$15.9M
(-6.5%)
Cap. Flow
-$6.79M
Cap. Flow
% of AUM
-2.99%
Top 10 Holdings %
Top 10 Hldgs %
7.9%
Holding
407
New
8
Increased
60
Reduced
329
Closed
10
Top Buys
Top Sells
Sector Composition
| 1 | Healthcare | 25.28% |
| 2 | Real Estate | 19.7% |
| 3 | Energy | 13.28% |
| 4 | Utilities | 12% |
| 5 | Materials | 10.51% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
326
Akero Therapeutics
AKRO
$3.58B
| $160K | 0.07% |
7,146
-380
| -5% | -$8.51K |
|
|
MTEM
327
DELISTED
Molecular Templates, Inc.
MTEM
| $160K | 0.07% |
1,587
-83
| -5% | -$8.37K |
|
328
Keros Therapeutics
KROS
$633M
| $159K | 0.07% |
4,016
-213
| -5% | -$8.43K |
|
329
Madrigal Pharmaceuticals
MDGL
$9.65B
| $158K | 0.07% |
1,976
-102
| -5% | -$8.16K |
|
|
AFMD
330
DELISTED
Affimed
AFMD
| $157K | 0.07% |
2,542
-134
| -5% | -$8.28K |
|
331
BioAtla
BCAB
$31.5M
| $157K | 0.07% |
5,328
-275
| -5% | -$8.1K |
|
332
BridgeBio Pharma
BBIO
$10.2B
| $156K | 0.07% |
3,336
-173
| -5% | -$8.09K |
|
333
Cullinan Oncology
CGEM
$413M
| $156K | 0.07% |
6,925
-356
| -5% | -$8.02K |
|
|
CMRX
334
DELISTED
Chimerix, Inc.
CMRX
| $156K | 0.07% |
25,153
-1,319
| -5% | -$8.18K |
|
335
Taysha Gene Therapies
TSHA
$917M
| $154K | 0.07% |
8,268
-429
| -5% | -$7.99K |
|
336
Aldeyra Therapeutics
ALDX
$334M
| $152K | 0.07% |
17,296
-905
| -5% | -$7.95K |
|
337
Shattuck Labs
STTK
$74.2M
| $152K | 0.07% |
7,462
-392
| -5% | -$7.99K |
|
|
PRVB
338
DELISTED
Provention Bio, Inc. Common Stock
PRVB
| $151K | 0.07% |
23,667
-1,242
| -5% | -$7.92K |
|
339
Arrowhead Research
ARWR
$4.02B
| $150K | 0.07% |
2,403
-127
| -5% | -$7.93K |
|
340
Korro Bio
KRRO
$312M
| $150K | 0.07% |
426
-22
| -5% | -$7.75K |
|
341
Precigen
PGEN
$1.3B
| $150K | 0.07% |
30,149
-1,580
| -5% | -$7.86K |
|
|
RETA
342
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
| $150K | 0.07% |
1,486
-74
| -5% | -$7.47K |
|
343
Compugen
CGEN
$134M
| $149K | 0.07% |
24,979
-1,306
| -5% | -$7.79K |
|
344
CytomX Therapeutics
CTMX
$376M
| $149K | 0.07% |
29,358
-1,538
| -5% | -$7.81K |
|
345
Vor Biopharma
VOR
$248M
| $149K | 0.07% |
9,533
-493
| -5% | -$7.71K |
|
346
Applied Therapeutics
APLT
$68.2M
| $146K | 0.06% |
8,790
-457
| -5% | -$7.59K |
|
|
IGMS
347
DELISTED
IGM Biosciences
IGMS
| $146K | 0.06% |
2,213
-115
| -5% | -$7.59K |
|
348
Passage Bio
PASG
$22.8M
| $146K | 0.06% |
734
-39
| -5% | -$7.76K |
|
349
Denali Therapeutics
DNLI
$2.26B
| $143K | 0.06% |
2,830
-150
| -5% | -$7.58K |
|
350
Wave Life Sciences
WVE
$1.32B
| $143K | 0.06% |
29,090
-1,510
| -5% | -$7.42K |
|